“Immuno-engineering to Improve Immunotherapy”
(BOSTON) – Harvard’s “Immuno-engineering to Improve Immunotherapy” (i3) Center at the Wyss Institute awarded cancer-immunologist Rizwan Romee, M.D. with a second annual grant. Romee and his group at the Dana-Farber Cancer Institute (DFCI) will develop natural killer (NK) cell-based therapies by leveraging biomaterials-based immune cell amplifying and educating approaches pioneered by David Mooney’s group at the Wyss Institute and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS). This strategy could offer a new opportunity to advance immunotherapy to solid tumors, which thus far mostly have eluded innovative immunotherapies designed to turn patients’ immune system against cancer cells in their bodies.
ارسال به دوستان